관절강내 투여를 위한 피록시캄과 히드록시프로필-베타-시클로덱스트린의 포접복 합체를 함유하는 히알우론산 젤 제형 (Hyaluronic acid gel formulation containing Piroxicam : Hydroxypropyl-β-cyclodextrin inclusion complex for intra-articular delivery)

서지정보

· 발행기관 : 한국생체재료학회
· 수록지 정보 : 생체재료학회지 / 13권 / 1호 / 1 ~ 6페이지
· 저자명 : 최규현, 정서영

초록

To improve solubility and dissolution rate of piroxicam (PX), a poor soluble drug, the inclusion complex of PX with
hydroxypropyl-β-cyclodextrin (HPβCD) in molar ratio of 1:1 was prepared by freeze-drying method. Then, the inclusion
complex of PX with HPβCD was investigated by Differential scanning calorimetry, X-ray diffractometry and FTIR
spectroscopic studies. The dissolution study showed that solubility and dissolution rate of PX were significantly
enhanced by making PX-HPβCD inclusion complex. To develop the sustained release formulation for intra-articular (IA)
administration of PX, Hyaluronic acid (HA) / Chondroitin sulfate (CS) gel formulations were prepared by dispersing the
inclusion complex of PX with HPβCD to the gels. The prepared gel formulations containing PX as an inclusion complex
were evaluated by measuring viscosity and in vitro release. As a result, the viscosity of gel formulations was increased
by adding the CS and the release of PX was more retarded as the viscosity of gel formulations increase. Also, it was
revealed that the HA (1% w/v) / CS (4% w/v) gel formulation could continuously release the PX for 24 hours in vitro.
Thus, HA / CS gel formulation containing PX as an inclusion complex might be used as a sustained release formulation
for IA administration.

영어초록

To improve solubility and dissolution rate of piroxicam (PX), a poor soluble drug, the inclusion complex of PX with
hydroxypropyl-β-cyclodextrin (HPβCD) in molar ratio of 1:1 was prepared by freeze-drying method. Then, the inclusion
complex of PX with HPβCD was investigated by Differential scanning calorimetry, X-ray diffractometry and FTIR
spectroscopic studies. The dissolution study showed that solubility and dissolution rate of PX were significantly
enhanced by making PX-HPβCD inclusion complex. To develop the sustained release formulation for intra-articular (IA)
administration of PX, Hyaluronic acid (HA) / Chondroitin sulfate (CS) gel formulations were prepared by dispersing the
inclusion complex of PX with HPβCD to the gels. The prepared gel formulations containing PX as an inclusion complex
were evaluated by measuring viscosity and in vitro release. As a result, the viscosity of gel formulations was increased
by adding the CS and the release of PX was more retarded as the viscosity of gel formulations increase. Also, it was
revealed that the HA (1% w/v) / CS (4% w/v) gel formulation could continuously release the PX for 24 hours in vitro.
Thus, HA / CS gel formulation containing PX as an inclusion complex might be used as a sustained release formulation
for IA administration.

참고자료

· 없음